effect overlay
activetrials
Epilepsy
Epilepsy
BHV7000 Idiopathic Generalized Epilepsy 304

A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic

HREC: 2024.147
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact:
Funding: Commercial
Epilepsy
Epilepsy
BHV7000 Refractory Focal Onset Epilepsy OLE 303

A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

HREC: 2024.146
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact:
Funding: Commercial
Epilepsy
Epilepsy
BHV7000 Refractory Focal Onset Epilepsy 303

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

HREC: 2024.145
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact:
Funding: Commercial
Epilepsy
Epilepsy
ENIGMA

Use of deep learning to support clinical decision making for resective surgery in drug resistant focal epilepsy

HREC: 2022.355
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Merran Courtney
Funding: Non-Commercial
Epilepsy
Epilepsy
Drug Resistant Epilepsy

Drug Resistant Epilepsy

HREC: 2019.321
Principal Investigator: Prof Patrick Kwan
Coordinator contact:
Funding: Non-Commercial